ArticleJournal of veterinary internal medicine2019
Intra-arterial renal infusion of autologous mesenchymal stem cells for treatment of chronic kidney disease in cats: Phase I clinical trial.
Article in Journal of veterinary internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Validation of Optimal Reference Genes for qRT-PCR in Adipose- and Uterine-Derived Feline Mesenchymal Stem Cells.Veterinary sciences · 2026Article
- Cell based therapy in chronic kidney disease: emerging evidence for a fifth pillar in guideline directed medical therapy.Clinical and experimental nephrology · 2026Review
- Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application.Frontiers in veterinary science · 2026Review
- Article
- Mesenchymal Stem Cells in Veterinary Medicine-Still Untapped Potential.Animals : an open access journal from MDPI · 2025Review
- Case Report: Allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease.Frontiers in veterinary science · 2025Article
- Feline Adult Adipose Tissue-Derived Multipotent Stromal Cell Isolation and Differentiation.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Innovations in Stem Cell Therapy for Diabetic Wound Healing.Advances in wound care · 2023Review
- Stem Cell Therapy for Aging Related Diseases and Joint Diseases in Companion Animals.Animals : an open access journal from MDPI · 2023Review
- Article
- Viability, yield and expansion capability of feline MSCs obtained from subcutaneous and reproductive organ adipose depots.BMC veterinary research · 2021Article
- Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study.Frontiers in veterinary science · 2021Article
- Article
- Article
- Intra-arterial renal infusion of autologous mesenchymal stem cells for treatment of chronic kidney disease in cats: Phase I clinical trial.Journal of veterinary internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThere are no known treatments that halt or reverse chronic kidney disease (CKD) in cats. In rodent models, stem cell treatment has been associated with improvement in renal function parameters, especially when stem cells were delivered intra-arterially to the kidney. To date, only IV and intrarenal stem cell infusions have been studied in cats with CKD with no clinically relevant improvement noted.
objectiveTo assess the safety and feasibility of intra-arterial delivery of autologous mesenchymal stem cells (MSC) in stromal vascular fraction (SVF) to the kidney in cats with CKD. ANIMALS: Five client-owned domestic cats with International Renal Interest Society stage III CKD.
methodsProspective cohort study (phase I clinical trial). Adipose tissue was harvested from study animals on day 0. On days 2 and 14, an infusion of MSC in SVF was administered into the renal artery via the femoral or carotid artery using fluoroscopic guidance. Serum creatinine and blood urea nitrogen concentration, plasma iohexol clearance, and quality of life assessments were monitored between days 0 and 90.
resultsThe procedure was performed successfully in all cats. No severe adverse events were observed in any cat during the study period. CONCLUSIONS AND CLINICAL IMPORTANCE: Intra-arterial infusion of MSC into the renal artery in CKD cats was feasible and safe within a 3-month postoperative period. Efficacy and long-term safety have yet to be established. This procedure requires careful technique and training.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.